David Hsieh, M.D. Assistant Professor School Medical School Department Internal Medicine You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography David Hsieh, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Hematology and Oncology. Originally from Tucson, Arizona, Dr. Hsieh earned his medical degree at the University of Arizona College of Medicine. He completed internal medicine residency training at Mount Auburn Hospital in Cambridge, Massachusetts. He then completed advanced training through a fellowship in hematology and oncology at UT Southwestern Medical Center. A Diplomate of the American Board of Internal Medicine in medical oncology, Dr. Hsieh joined the UT Southwestern faculty in 2019. Dr. Hsieh leads clinical trials testing new drugs for liver cancers including hepatocellular carcinoma and cholangiocarcinomas. His other research interests include translational studies to understand mechanisms behind the variable effectiveness of cancer therapies between patients and the development of treatment biomarkers. He also researches processes, policies, and biases in scientific research and medicine. Dr. Hsieh's clinical interests include hepatocellular carcinoma and biliary tract cancers including cholangiocarcinomas and gall bladder cancers. Dr. Hsieh's awards and honors include an Early Career Investigator Award from the Cancer Prevention and Research Institute of Texas. Education Medical School University of Arizona College of Medicine-Phoenix (2013) Residency Mount Auburn Hospital (2016), Internal Medicine Fellowship UT Southwestern Medical Center (2019), Hematology Oncology Research Interest Cholangiocarcinoma Hepatocellular carcinoma Immunotherapy Liver cancer Mechanisms of drug resistance Predictive biomarkers Publications Featured Publications Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation. Hsiehchen D, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H, Cancer Cell 2024 Nov The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial. Hsiehchen D, Beg MS, Kainthla R, Lohrey J, Kazmi SM, Khosama L, Maxwell MC, Kline H, Katz C, Hassan A, Kubota N, Siglinsky E, Pillai AK, Youssoufian H, Mockbee C, Culm K, Uhlik M, Benjamin L, Brekken RA, Ahn C, Singal AG, Zhu H, Hoshida Y, Yopp AC, Nat Commun 2024 Mar 15 1 2178 Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers. Muquith M, Espinoza M, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H, Hsiehchen D, Nat Cancer 2024 Mar Lengthy and Variable Delays in Oncology Drug Coverage Determination. Haque W, Rana I, Zahid S, Hsiehchen D, JAMA Oncol 2023 Dec 9 12 1728-1729 Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH, Lancet 2023 Oct Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma. Lim M, Muquith M, Miramontes B, Lee CJ, Espinoza M, Huang YH, Hsiehchen D, Hepatology 2023 Jun EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma. Lim M, Franses JW, Imperial R, Majeed U, Tsai J, Hsiehchen D, Gastroenterology 2023 May 164 6 1006-1008.e3 Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150. Espinoza M, Muquith M, Lim M, Zhu H, Singal AG, Hsiehchen D, Gastroenterology 2023 Mar Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Hsiehchen D, Bucheit L, Yang D, Beg MS, Lim M, Lee SS, Kasi PM, Kaseb AO, Zhu H, Nat Commun 2022 Dec 13 1 7477 Clonal hematopoiesis and differential outcomes after immune checkpoint blockade. Hsiehchen D, Sfreddo HJ, Zhao K, Han CY, Morris LGT, Cancer Cell 2022 Oct 40 10 1071-1072 Results 1-10 of 16 1 2 Next Last Honors & Awards CPRIT Early Clinical Investigator Award (2020) ASH Research Training Award for Fellows (2018)
